Renal participation in cardiovascular risk inessential hypertension

Expert Review of Cardiovascular Therapy

Volumn 1, Issue 2, 2003, Pages 309-315

  Ruilope, Luis m ^a   Segura, Julián ^a   Campo, Carlos ^a   Rodicio, José l ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

cardiovascular risk; creatinine clearance; hypertension; microalbuminuria; proteinuria; renal failure; serum creatinine

Indexed keywords

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FAILURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE; PREVALENCE; RISK FACTORS;

EID: 2142718258     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.1.2.309     Document Type: Review

References (60)

1. Woolfson RG, de Wardener HE. Primary renal abnormalities in hereditary hypertension. IGdney Int. 50, 717 – 731 (1996).
2. Ruilope LM, Lahera V, Rodicio JL et al Are renal hemodynamics a key factor in the development and maintenance of hypertension in humans? Hypertension 23, 3 – 9 (1994).
3. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function therapeutic implications. Hypertens. 14, 1259 – 1263 (1996).
4. Perera GA. Hypertensive vascular disease: description and natural history. J. Chronic Dis. 1, 33 – 42 (1955).
5. Madhavan S, Stockwell D, Cohen H, Alderman MET. Renal function during antihypertensive treatment. Lancet 345, 749 – 751 (1995).
6. Levey AS, Bosch JP, Lewis JB et al A more accurate method to estimate glomerular rate from serum creatinine: a new prediction equation. 'Modification of Diet in Renal Disease Study Group'. Ann. Intern. Med. 130, 461 – 470 (1999).
7. Culleton BF, Larson MG, Wilson PWF et al Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. IGdney int. 56, 2214 – 2219 (1999).
8. Ruilope LM, Salvetti A, Jamerson K et al Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) Study. J. Am. Soc. Nephrol. 12, 218 – 225 (2001).
9. Ruilope LM, Palmer C, de Leeuw P et al Evaluation of different parameters of renal function as predictors of primary outcome in the INSIGHT study. J. Hypertens. 19 (Suppl. 2), S223 (2001) (Abstract).
10. Mann JFE, Gerstein HC, Pogue J et al Renal insufficiency as predictor of cardiovascular outcomes and impact of ramipril: the HOPE randomization trial. Ann. Intern. Med. 134, 629 – 636 (2001)
11. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Curl: Opin. Nephrol. Hypertens. 2, 962 – 967 (1993).
12. Minram A, Ribstein J, DuCalair G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension 23 \(Pt 2), 1018 – 1021 (1994).
13. Luque M, Garcia-Robles R, Tamargo J, Ruilope LM. Blood pressure control in hospital located hypertension units. Hypertension 37, 030 (2001) (Abstract).
14. Cuspidi C, Lonati L, Sampieri L et al Blood pressure control in a hypertension hospital clinic. J. Hypertens. 17, 835 – 841 (1999).
15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch. Intern. Med. 157, 2413 – 2446 (1997).
16. Guidelines Subcommittee, World Health Organization—International Society of Hypertension Guidelines for the management of hypertension. I Hypertens. 17, 151 – 183 (1999).
17. Coresh J, Wei GL, McQuillan G et al Prevalence of high blood pressure and elevated serum creatinine level in the United States. Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 161, 1207 – 1216 (2001).
18. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic americans: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 13, 1338 – 1349 (2002).
19. Shulman NB, Ford CE, Hall WD et al Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 13 (Suppl. I), 180 – 193 (1989).
20. Fried LP, Kronmal RA, Newman AB et al Risk factors for 5-year mortality in older adults: The Cardiovascular Health Study. JAMA 279, 585 – 592 (1998).
21. Zanchetti A, Hansson L, Dahlöf B et al Effects of individual risk factors on the incidence of cardiovascular events in the hypertensive patients of the Hypertension Optimal Treatment (HOT) study. I Hypertens;19, 1149 – 1160 (2001). Serum creatinine as a powerful predictor of mortality
22. Tracy RE, Malcom GT, Oalmann MC et al Nephrosclerosis in coronary heart disease. Mod. Pathol 7, 301 – 309, 1994
23. Tracy RE, Strong JP, Newman III WP et al Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25-54 years. IGckey Int. 49, 564 – 570 (1996).
24. Baker DW. Prevention of heart failure. Camliovasc. Fail 8, 333 – 346 (2002).
25. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular dysfunction. J. Am. Coll Camliol 35, 681 – 689 (2000).
26. Gottlieb SS, Skettino SI, Wolff A et al Effects of BG9719 (CVT-124) an Aradenosine receptor antagonist and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am Coll. Camliol 35, 56 – 59 (2000).
27. Schrier RVV, Abraham WT Hormones and hemodynamics in heart failure. N Engl. J. Med. 341, 577 – 585 (1999).
28. Ljungmann S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39 (Suppl. 4), 10 – 21 (1990).
29. Middlekauff HR, Nitzsche EU, Hoh CK et al Exaggerated renal vasoconstriction during exercise in heart failure patients. Circulation 101, 784 – 789 (2000).
30. Volpe M, Magri P, Rao MA, C et al Intrarenal determinants of sodium retention on mild heart failure: effects of angiotensin converting enzyme inhibition. Hypertension 30(Pt 1), 168 – 176 (1997).
31. Magri P, Rao MA, Cangianello S et al Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 98, 2849 – 2854 (1998).
32. Hillege HL, Girbes ARJ, de Kam PJ et al Renal function, neurohumoral activation and survival in patients with chronic heart failure. Chrulation 102,203-210 (2000). Impaired renal function is a stronger predictor than impaired cardiac function in patients with congestive heart failure.
33. Hillege HL, van Guist WH, Kngma JH et al Myocardial infarction is associated with renal function lose which is counteracted by ACE inhibition. j Am. Soc. Nephrol 10, 5A (1999) (Abstract).
34. Kannel WB, McGee DL. Epidemiology of sudden death: insights from the Framingham Study. Carcliovasc. Clin. 15, 93 – 105 (1985).
35. Gottlieb SS, McCarter RJ, Vogel RA. Effect of I3-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N EngL I Med. 339, 89 – 97 (1998).
36. McCullough PA, Soman SS, Shah SS et al Risks associated with renal dysfunction in patients in the coronary care unit. j Am. Coll Carcliol 36, 679 – 684 (2000).
37. Rubenstein MET, Harrell LC, Sheynberg BV et al Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 102, 2966 – 2972 (2000).
38. Gruberg L, Mintz GS, Mehran R et al The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J. Am. Coll Carcliol 36, 1542 – 1548 (2000).
39. Marso SP, Ellis SG, Gurm HS, Lytle BW, Topol EJ. Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. Am. Heart 139, 939 – 944 (2000).
40. Berton G, Citro T, Palmieri R et al Albumin excretion rate increases during acute myocardial infarction and strongly predicts early mortality. Circulation 96, 3338 – 3345 (1997). The albumin excretion rate increases during myocardial infarction.
41. Kannel WB, Stampfer MJ, Castelli Verter J. The prognostic significance of proteinuria. Am. Heart J. 108, 1347 – 1352 (1984).
42. Samuelsson Hypertension in middle-aged man: management, morbidity and prognostic factors during long-term hypertensive care. Acta Med. Scand Suppl 702, 71 – 79 (1985).
43. Brown MJ, Palmer CR, Castaigne A et al Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blacker or diuretic in the International Nifedipine GITS study: Intervention as a goal in Hypertension Treatment (INSIGHT). Lancet356, 366 – 372 (2000).
44. Ruilope LM, Rodicio JL. Microalbuminuria in clinical practice. I6dney: Cutr Surv.14brIcl Lit. 4, 211 – 216 (1995).
45. Agrawal B, Berger A, Wolf K, Luft PC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. Hypertens. 14, 223 – 228 (1996).
46. Campese VM, Bianchi S, Bigazzi R Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? CUM Opin. NEphml. Hypertens. 9, 143 – 147 (2000).
47. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl. I Med 343, 141 – 144 (2000).
48. De Leeuw PW, Thijs L, Birkenhager WH et al Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial.' Am. Soc. NEphml. 13, 2213 – 2222 (2002).
49. Brod J, Bahlman J, Cachoven M, Pretschner PD. Development of hypertension in renal disease. Clin. Li 64, 141 – 152 (1983).
50. Hall JE. Pathophysiology of obesity hypertension. Cutr Hypertens. Rep 2, 139 – 147 (2000).
51. Remuzzi G. Cigarette smoking and renal function impairment. Am J. I6dney Dis. 33, 807 – 813 (1999).
52. Segura J, Campo C, Rodicio JL, Ruilope LM. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 38 \(Pt 2), 645 – 649 (2001).
53. Wright JT Jr, Bakris G, Greene T et al for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JA/V/A 288, 2421 – 2431 (2002).
54. Kronenberg F, Kuen E, Ritz E et al Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol 11, 105 – 115 (2000).
55. Fliser D, Pacini G, Engelleiter R et al Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 53, 1343 – 1347 (1998).
56. Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol 161, 2524 – 2532 (1998).
57. London GM, Guerin AP, Pannier B et al Increased systolic pressure in chronic uremia: role of arterial wave reflection. Hypertension 20, 10 – 19 (1992).
58. Dengel D, Goldberg AP, Mayuga RS et al Insulin resistance, elevated glomerular filtration fraction and renal injury. Hypertension 28, 127 – 132 (1996).
59. Gross V, Schneider W, Schunk WH, Mervaala E, Luft PC. Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. I Am. Soc. Nephrol 10, 1430 – 1439 (1999).
60. Reaven GM, Lithell H, Landsberg L. Mechanisms of disease: hypertension and associated metabolic abnormalities — the role of insulin resistance and the sympathoadrenal system. N Engl. J Med 334, 74 – 381 (1996).